Andrew
Senior Member
- Messages
- 2,517
- Location
- Los Angeles, USA
We hear that Japan tested the blood supply and found XMRV. Where is this published? Who did the testing? What was the method?
Welcome to Phoenix Rising!
Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of, and finding treatments for, complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia, long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.
To become a member, simply click the Register button at the top right.
Here is the reference that was given in the Erlwein et al. study. I couldn't find a paper, and I'm wondering if there is no published paper. It was presented at a symposium.
2. Furuta RA, Miyazawa T, Sugiyama T, Kimura T, Hirayama F, et al. The Prevalence of Xenotropic Murine Leukemia Virus-related Virus in Healthy Blood Donors in Japan. Cold Spring Harbor Retrovirus Symposium. 2009
Regarding this point, it is also of interest that Furuta et al. [33], recently reported the detection by Western blot of antibodies specific for the XMRV Gag protein in blood bank samples from prostate cancer patients and healthy donors, but no Env-specific antibodies.
Kim_;48269]gracenote is correct. There is no paper, only a symposium report. I searched high and lo for more info, but came up empty handed.
Here is the reference that was given in the Erlwein et al. study. I couldn't find a paper, and I'm wondering if there is no published paper. It was presented at a symposium.
2. Furuta RA, Miyazawa T, Sugiyama T, Kimura T, Hirayama F, et al. The Prevalence of Xenotropic Murine Leukemia Virus-related Virus in Healthy Blood Donors in Japan. Cold Spring Harbor Retrovirus Symposium. 2009
"We conclude that XMRV infection is prevalent among both prostate cancer patients and healthy individuals in Japan. Although our study had a limited sample size, the prevalence among blood donors as determined by identifying XMRV-specific antibodies was found to be 1.7%, while that among prostate cancer patients was found to be 6.3%"